Dabur Oncology

Rediff.com » News » Dabur Oncology

News for Dabur Oncology

Business

Dabur Pharma eyes US, Europe

Dabur Pharma, a leading player in the domestic oncology segment, is busy finalising its marketing strategies for EU, the US and Australia. The company is expecting five regulatory approvals in......

Dabur may announce 125-150% dividend

Dabur India is expected to announce the highest ever 125-150 per cent dividend as well as the swap ratio for the proposed demerger of pharma and FMCG businesses at its board meeting scheduled to be......

Domestic pharma firms take lead in R&D tie-up

The domestic pharmaceuticals industry has proven its mettle once again with Glenmark Pharmaceuticals announcing the receipt of euro 25 million from German drug major Merck as upfront payment for a......

Alembic buys Dabur's non-oncology business

Dabur Pharma has sold its entire non-oncology business to Alembic for approximately Rs 167 crore (Rs 1.67 billion). With the deal, Dabur becomes the country's first and only speciality drug company......

Dabur on fast track to good health

After hiving off its non-oncology drugs business last year, the Dabur group recently divested its entire stake in Dabur Pharma to Fresenius Kabi, a 100 per cent subsidiary of the Germany-based......

Rediff News

Dabur Oncology

News for Dabur Oncology

Dabur Pharma eyes US, Europe

Dabur may announce 125-150% dividend

Domestic pharma firms take lead in R&D tie-up

Alembic buys Dabur's non-oncology business

Dabur on fast track to good health

Top Coverage News

World Test Championship 2023

Manipur's Tragedy

IPL 2023

Sri Lanka's Tour of India 2023

GUJARAT, HIMACHAL GO TO POLLS